Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TNFRSF1A | P19438 | 3/20 | 0.60 |
| ▸ | APP | P05067 | 4/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.57 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.57 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512551 | 1.00 | KDM4E (0.64) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL22555959 | 0.97 | KDM4E (0.62) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL7813956 | 0.92 | KDM4E (0.69) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL7813952 | 0.92 | KDM4E (0.69) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL4843115 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL4843101 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL22555962 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1HTR1AHPGDHTR2C | |
| SCHEMBL5848694 | 0.90 | KDM4E (0.66) | KDM4EALDH1A1LMNAAPPPDE4A | |
| SCHEMBL5848689 | 0.90 | KDM4E (0.66) | KDM4EALDH1A1LMNAAPPPDE4A | |
| SCHEMBL27743558 | 0.88 | TNFRSF1A (0.60) | KDM4EALDH1A1HTR1AHPGDHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9518022-B2 | Anti-HIV compounds | PROSETTA ANTIVIRAL INC. (US) | 2016-12-13 | — | — | US | disclosed |
| WO-2016100391-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150073158-A1 | METHOD FOR PREPARING FUROFURAN LIGNAN COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2015-03-12 | — | — | US | disclosed |
| WO-2002074300-A1 | COMPOSITION FOR TREATING ARTERIOSCLEROSIS COMPRISING 3-(4'-HYDROXYL-3',5'-DIMETHOXYPHENYL)PROPIONIC ACID OR ITS DERIVATIVES | DONG WHA PHARM. IND. CO., LTD. (KR) | 2002-09-26 | — | — | WO | disclosed |
| EP-0628311-B1 | Xanthine-Derivatives as Antidepressants | KYOWA HAKKO KOGYO KK (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-0565377-B1 | Therapeutic agents for use in the treatment of Parkinson's Disease | KYOWA HAKKO KOGYO KK (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5587378-A | ADMINISTERING A SUBSTITUTED XANTHINE COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5543415-A | ADMINISTERING A XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-08-06 | — | — | US | disclosed |
| US-5484920-A | XANTHINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0628311-A1 | ANTIDEPRESSANT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| EP-0565377-A1 | Therapeutic agents for use in the treatment of parkinson's disease | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| US-3995054-A | MITICIDES | ZOECON CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
| US-3975429-A | Cyclopropanemethyl esters of cinnamic acid and derivatives thereof | ZOECON CORPORATION (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885ALDH1A1 3748/4885HTR1A 3014/4885 |
| US-20150073158-A1 | METHOD FOR PREPARING FUROFURAN LIGNAN COMPOUND | CYP4F2, UGT1A7, UGT1A3 | KDM4E 1126/4885ALDH1A1 137/4885HTR1A 2642/4885 |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885ALDH1A1 3748/4885HTR1A 3014/4885 |
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | MAVS, SARS1, NFATC1 | KDM4E 448/4885ALDH1A1 3741/4885HTR1A 3557/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885ALDH1A1 3748/4885HTR1A 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.